20 articles
A landmark ACSM consensus statement delivers the first evidence-based exercise guidelines for children and adolescents during and after cancer treatment.
Redirecting glucose metabolism during T cell expansion dramatically improves cancer immunotherapy effectiveness.
New research shows how activating PKM2 enzyme enhances CD8 T cell function and improves anti-PD1 cancer therapy effectiveness.
Novel treatment triggers ferroptosis in cancer cells while activating immune responses that further enhance cancer cell death.
Ketogenic diet metabolite enhances CAR T cell metabolism and tumor control in multiple cancer models
A new Science paper reveals that mitochondrial fitness in dendritic cells controls antitumor immunity — and can be targeted to boost immunotherapy.
New fusion model combines hypoxia and immune markers to predict hepatocellular carcinoma treatment success non-invasively.
Metabolite supplement protects heart from chemo toxicity and enhances tumor suppression in breakthrough dual-action study.
New review reveals how targeting mitochondria in cancer cells could overcome immunotherapy resistance and enhance anti-tumor responses.
A comprehensive review reveals how iron-driven cell death can be exploited to treat ATC, one of the most lethal human cancers.
Novel nanoplatform delivers copper and iron ions to trigger both ferroptosis and cuproptosis in cancer cells.
A phase 3 trial finds scheduling immunochemotherapy before 3 PM nearly doubles progression-free and overall survival in NSCLC patients.
A novel liquid biopsy scoring tool called MinerVa-Delta predicted survival in advanced lung cancer with striking accuracy, even when imaging was ambiguous.
Engineered green tea compound nanoparticles activate cellular powerhouses to suppress tumor growth and improve immune response against melanoma.
Novel nanoparticle combines protein degrader with light therapy to reprogram cancer metabolism and eliminate breast tumors.
A new strategy combining a TROP2-targeting drug with osimertinib may delay the inevitable resistance that undermines EGFR-mutant lung cancer treatment.
Scientists found that inhibiting USP30, a mitochondrial enzyme, restores immune cell function and shrinks tumors in mice.
Scientists identify a mitochondria-proteasome-haem pathway that silences immune cells — and show bortezomib can fix it in CAR-T therapy.
ASTER 70s trial compares treatment intensities for women 70+ with genomically high-risk breast cancer to optimize outcomes while minimizing toxicity.
Comprehensive review reveals how mitochondrial dysfunction fuels cancer progression and identifies promising therapeutic opportunities.
